Alibaba Health Announces Leadership Transition: Wang Lei Steps Down as CEO, Shen Difan Appointed as Successor

VCBeat (WeChat ID: vcbeat) has learned that on the evening of March 29, Alibaba Health announced its latest board appointments: Wang Lei, the former Chief Executive Officer (CEO), will step down from his CEO role and return to work for Alibaba Group, the controlling shareholder of Alibaba Health, while continuing to serve as a non-executive director. Shen Difan, former General Manager of Alibaba’s AliExpress with extensive cross-sector experience at Alibaba, will assume the position of CEO of Alibaba Health.

In the announcement, Eddie Wu, Senior Vice President of Alibaba Group and Chairman of the Board of Ali Health, stated, “We extend our gratitude to Wang Lei for his achievements and contributions during his tenure at Ali Health. During his term, Mr. Wang assembled an outstanding management team, established a comprehensive pharmaceutical and healthcare business platform, and successfully executed the company’s phased strategic initiatives, laying a solid foundation for Ali Health’s rapid future growth. At the same time, we welcome Shen Difan to his new role. We expect him to leverage his extensive expertise in internet platform operations to lead Ali Health in consolidating its existing business advantages and expanding into new markets, thereby further advancing the development of Alibaba’s key ‘Double H’ strategy.”

The announcement revealed that Shen Difan, the newly appointed CEO of Alibaba Health, is also a “veteran Alibaba employee” with over 10 years of service at the company. He has held key positions across multiple functions—including technology, product, and operations—in various business units such as Alibaba’s B2B division, the Security Department, and AliExpress. Over the past six years, as General Manager of AliExpress, Shen Difan has driven the business’s rapid expansion into international markets and achieved overseas localization of the AliExpress brand.

Meanwhile, in an email addressed to all employees of Alibaba Health, Wu Yongming stated that since Alibaba launched its “Double H” (Health and Happiness) strategy in 2015, the company has consistently positioned Alibaba Health as its flagship platform in the pharmaceutical and healthcare sector, with continued increases in investment in both human resources and capital.

“Alongside this personnel change, the synergy of various resources between the Group and Alibaba Health will continue to improve, and support for Alibaba Health will be further upgraded,” wrote Wu Yongming.